dc.contributor.author | Stella, Valentino J. | |
dc.contributor.author | Charman, W. N. A. | |
dc.contributor.author | Naringrekar, V. H. | |
dc.date.accessioned | 2011-09-30T16:37:01Z | |
dc.date.available | 2011-09-30T16:37:01Z | |
dc.date.issued | 1985-05 | |
dc.identifier.citation | Prodrugs: Do They Have Advantages in Clinical Practice? V.J. Stella, W.N.A. Charman and V.H. Naringrekar, Drugs, 29, 455-473 (1985). | |
dc.identifier.issn | 0012-6667 | |
dc.identifier.uri | http://hdl.handle.net/1808/8087 | |
dc.description | This is the published version, also available from the publisher at http://adisonline.com/drugs/Abstract/1985/29050/Prodrugs__Do_They_Have_Advantages_in_Clinical.2.aspx | |
dc.description.abstract | Prodrugs are pharmacologically inactive chemical derivatives of a drug molecule that require a transformation within the body in order to release the active drug. They are designed to overcome pharmaceutical and/or pharmacokinetically based problems associated with the parent drug molecule that would otherwise limit the clinical usefulness of
the drug.
The scientific rationale, based on clinical pharmaceutical and chemical experience,
for the design of various currently used prodrugs is presented in this review. The examples presented are by no means comprehensive, but are representative of the different ways in which the prodrug approach has been used to enhance the clinical efficacy of various drug molecules. | |
dc.language.iso | en_US | |
dc.publisher | Adis Press Limited | |
dc.subject | Pro-drugs | |
dc.subject | Pharmaceutical chemistry | |
dc.title | Prodrugs: Do They Have Advantages in Clinical Practice? | |
dc.type | Article | |
kusw.kuauthor | Stella, Valentino J. | |
kusw.kudepartment | Pharmaceutical Chemistry | |
kusw.oastatus | fullparticipation | |
kusw.oaversion | Scholarly/refereed, publisher version | |
kusw.oapolicy | This item meets KU Open Access policy criteria. | |
dc.rights.accessrights | openAccess | |